Founded in 2003, Zhejiang Kangmu Animal Health Co., Ltd. is a group company focusing on animal treatment, animal health care and animal nutrition. It has the whole chain production capacity of chemical synthetic API, biological fermentation API and animal protection preparation products, and has a complete and strong marketing network. Headquartered in Chengbei Industrial Zone, Shengzhou City, Zhejiang Province, the company has five wholly-owned subsidiaries, including Zhejiang Kangmu Pharmaceutical Co., Ltd., Zhejiang Debo Biotechnology Co., Ltd., Zhejiang Zhixing Pharmaceutical Co., Ltd., Shandong Weiyan Biotechnology Co., Ltd. and Shanghai Weimu Biotechnology Co., Ltd.

        For a long time, the company has established the mission of "ensuring animal health and creating a harmonious life", the vision of "contributing valuable products to animal health users all over the world", and the business philosophy of "customer value, reasonable cost, effective scale and profit with human care". The company pays attention to industry cooperation, strengthens upstream and downstream technical cooperation, continues to explore cooperation with high-quality customers such as Zhongmu Co., Ltd., Sinopharm group, Qilu pharmaceutical, Wenshi group, new hope group and Haida group, and jointly explores the innovative pharmaceutical industry with domestic and foreign enterprises in the layout of new products. On the basis of strengthening the industry university research cooperation with well-known universities such as Zhejiang University, Shanghai Jiaotong University, Zhejiang University of technology, Fudan University and Nanjing Agricultural University and research institutions such as the Chinese Academy of Sciences, we continue to promote independent research and development, create our own high-throughput screening platform, cultivate our own synthetic biology, chemical synthesis and preparation R & D teams, and continuously improve the technical strength of the company.

        The main products of the company in the veterinary API sector include florfenicol and tilmicosin; The main products of the company in the veterinary drug preparation sector include 20%, 30% florfenicol powder and 20%, 37.5% tilmicosin premix, supplemented by doxycycline, enrofloxacin and other series of products; Feed additives mainly include β- Carotene and cantharidin yellow series focus on the field of insect repellents in the pet medicine sector. Feed additives and pet medicine companies mainly adopt biosynthesis, which has strong competitive advantages in product cost and bioavailability; In terms of reserves of synthetic biological products, there are mainly a series of products such as tylosin and astaxanthin.

        In the future, the company will increase R & D investment, strengthen foreign cooperation and speed up the R &  D of new products; Expanding production capacity, reducing costs, improving competitiveness and terminal control, adhering to the values of "seriousness, integrity and innovation" and the development concept of "safety, green and sharing", we strive to build the company into an international production base of veterinary medicine products and contribute valuable products to animal health users all over the world.